These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. [EFFICACY, PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF INTRAVENOUS C1 INHIBITOR FOR LONG-TERM PROPHYLAXIS AND TREATMENT OF BREAKTHROUGH ATTACKS IN JAPANESE SUBJECTS WITH HEREDITARY ANGIOEDEMA: A PHASE 3 OPEN-LABEL STUDY]. Fukunaga A, Morita E, Miyagi T, Eto K, Shimizu A, Kagami S, Yamamoto H, Vardi M, Tang Y, Wang Y, Hide M. Arerugi; 2020; 69(3):192-203. PubMed ID: 32435020 [Abstract] [Full Text] [Related]
43. Clinical presentation, pathophysiology, diagnosis, and treatment of acquired and hereditary angioedema: Exploring state-of-the-art therapies in RI. Guo C, Settipane RA. R I Med J (2013); 2016 Jun 01; 99(6):41-4. PubMed ID: 27247973 [Abstract] [Full Text] [Related]
44. Treatment of hereditary angioedema: a review (CME). Bhardwaj N, Craig TJ. Transfusion; 2014 Nov 01; 54(11):2989-96; quiz 2988. PubMed ID: 24735226 [Abstract] [Full Text] [Related]
49. Management and prevention of hereditary angioedema attacks. Lumry WR. Am J Manag Care; 2013 Jun 01; 19(7 Suppl):s111-8. PubMed ID: 23844783 [Abstract] [Full Text] [Related]
50. Pasteurized and nanofiltered, plasma-derived C1 esterase inhibitor concentrate for the treatment of hereditary angioedema. Bork K. Immunotherapy; 2014 Jun 01; 6(5):533-51. PubMed ID: 24635050 [Abstract] [Full Text] [Related]
51. Advances in Hereditary Angioedema: The Prevention of Angioedema Attacks With Subcutaneous C1-Inhibitor Replacement Therapy. Lumry W, Templeton T, Omert L, Levy D. J Infus Nurs; 2020 Jun 01; 43(3):134-145. PubMed ID: 32287168 [Abstract] [Full Text] [Related]
53. Current options for prophylactic treatment of hereditary angioedema in the United States: patient-based considerations. Gower RG, Lumry WR, Davis-Lorton MA, Johnston DT, Busse PJ. Allergy Asthma Proc; 2012 Jun 01; 33(3):235-40. PubMed ID: 22584192 [Abstract] [Full Text] [Related]
54. Hereditary angiodema: a current state-of-the-art review, VI: novel therapies for hereditary angioedema. Frank MM. Ann Allergy Asthma Immunol; 2008 Jan 01; 100(1 Suppl 2):S23-9. PubMed ID: 18220149 [Abstract] [Full Text] [Related]
56. Hereditary angioedema with normal C1 inhibitor in a French cohort: Clinical characteristics and response to treatment with icatibant. Bouillet L, Boccon-Gibod I, Launay D, Gompel A, Kanny G, Fabien V, Fain O, IOS Study Group. Immun Inflamm Dis; 2017 Mar 01; 5(1):29-36. PubMed ID: 28250922 [Abstract] [Full Text] [Related]
58. Biochemical comparison of four commercially available C1 esterase inhibitor concentrates for treatment of hereditary angioedema. Feussner A, Kalina U, Hofmann P, Machnig T, Henkel G. Transfusion; 2014 Oct 01; 54(10):2566-73. PubMed ID: 24805006 [Abstract] [Full Text] [Related]
60. Treatment of episodes of hereditary angioedema with C1 inhibitor: serial assessment of observed abnormalities of the plasma bradykinin-forming pathway and fibrinolysis. Joseph K, Tholanikunnel TE, Kaplan AP. Ann Allergy Asthma Immunol; 2010 Jan 01; 104(1):50-4. PubMed ID: 20143645 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]